Propanc Biopharma, Inc.
PPCB· Nasdaq
PPCBPropanc Biopharma, Inc.
Filed Nov 14, 2023 · 10-Q · 45 days after period end · 0001493152-23-040980
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Net Income | -$350.87K | -$617.30K | -$490.66K | -$425.55K |
| EPS Diluted | -$0.04 | -$2.13 | -$0.02 | -$0.71 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Propanc Biopharma, Inc. · CIK 1517681 · Engraved from SEC EDGAR
ended Sep 30, 2023 · filed Nov 14, 2023 · 45 d after period end
